# Debate Matchup Judgment Report

**Claude Opus 4.8 (high)** vs **Baidu Ernie 5.1**

- Paired result: **Claude Opus 4.8 (high)**
- Mean entertainment: `7.67 / 10`
- Judge decisions: `6` across two side-swapped debates

**Motion:** Countries should treat access to essential medicines as grounds for compulsory licensing whenever prices exceed a defined affordability threshold.

## Debates and evidence

- [Debate A transcript](../../../transcripts/prop_0606__claude-opus-4-8-adaptive__ernie-5.1__s0__tpl_placement_active_20260320f.md): PRO = **Claude Opus 4.8 (high)**, CON = **Baidu Ernie 5.1**
- [Debate B transcript](../../../transcripts/prop_0606__ernie-5.1__claude-opus-4-8-adaptive__s1__tpl_placement_active_20260320f.md): PRO = **Baidu Ernie 5.1**, CON = **Claude Opus 4.8 (high)**
- [Public judge decision table](../../../judgments/judge_results__judge_blend_glm53_coverage_20260904a.csv)

## Debate A

- Transcript: [read the full debate](../../../transcripts/prop_0606__claude-opus-4-8-adaptive__ernie-5.1__s0__tpl_placement_active_20260320f.md)
- Roles: PRO = **Claude Opus 4.8 (high)**, CON = **Baidu Ernie 5.1**
- Judged result: Unanimous `3-0` for **Claude Opus 4.8 (high)**.
- Entertainment scores: `7`, `8`, `8`
- Mean signed raw margin (PRO+): `+2.00`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Grok 4.3 | A = Baidu Ernie 5.1 (CON); B = Claude Opus 4.8 (high) (PRO) | Claude Opus 4.8 (high) | +2.0 | +2.40 | 7.0 |
| Kimi K2.6 | A = Baidu Ernie 5.1 (CON); B = Claude Opus 4.8 (high) (PRO) | Claude Opus 4.8 (high) | +1.5 | +1.50 | 8.0 |
| Qwen 3.6 Max Preview | A = Claude Opus 4.8 (high) (PRO); B = Baidu Ernie 5.1 (CON) | Claude Opus 4.8 (high) | +2.5 | +2.50 | 8.0 |

### Judge Notes

- **Grok 4.3** (A = Baidu Ernie 5.1 (CON); B = Claude Opus 4.8 (high) (PRO)): B built the stronger case by turning A's hepatitis C example against them, exposing the voluntary-licensing gap in direct answers to pressure questions, and crystallizing present documented deaths versus unattached future chill in later rounds; A repeated ungrounded pipeline claims without naming missing drugs or neutralizing the speed concession.
  Most decisive rebuttal noted: B2.1 and B3.1/A3.1 exchange that forced A to defend voluntary deals while B's A1/A2 format directly answered and weighed the resulting contradiction.
- **Kimi K2.6** (A = Baidu Ernie 5.1 (CON); B = Claude Opus 4.8 (high) (PRO)): PRO established concrete present harms (insulin rationing, hepatitis C deaths) and showed compulsory licensing under TRIPS works, while CON could never name a specific future drug the price-trigger would prevent. PRO cleanly turned CON's Brazil example into an indictment of ad-hoc discretion and converted CON's "firms will price at 99% of the threshold" worry into proof the mechanism achieves affordability. CON's admission that voluntary licensing suffered "failures of speed" conceded the status quo kills people while negotiations drag on, and its pipeline arguments remained speculative abstraction against PRO's counted bodies.
  Most decisive rebuttal noted: PRO's turn of CON's threshold-gaming claim: showing that a firm pricing at 99% of an affordability line is precisely the affordable outcome the motion seeks, collapsing the worry that the rule would be gamed into meaninglessness.
- **Qwen 3.6 Max Preview** (A = Claude Opus 4.8 (high) (PRO); B = Baidu Ernie 5.1 (CON)): Side A wins by decisively controlling the central weighing clash: documented present harm versus speculative future R&D chill. A effectively managed burdens, noting that pharma revenue relies overwhelmingly on wealthy markets and that uncollectible launch prices in low-income regions cannot fund pipelines anyway. A's pressure questions exposed a critical weakness in B's alternative when B conceded voluntary licensing suffers from "failures of speed," which A correctly reframed as fatal when patients are actively dying. B repeatedly asserted a "documented pattern" of chilled innovation but failed to name a single missing drug or provide concrete support, weakening their epistemic grounding under closed-book constraints. A also cleanly flipped B's "99% threshold pricing" argument into a win for the motion. While B raised legitimate structural concerns about gaming and retaliation, A's sharper rebuttals, superior weighing, and more disciplined argumentation made the path to victory clear.
  Most decisive rebuttal noted: The exchange over voluntary licensing and speed. B claimed tiered pricing and voluntary deals already save lives, but A's Q1 forced B to concede these arrangements suffer from "failures of speed." A immediately weaponized this in R2 and Closing, arguing that when patients ration insulin, speed is the principle, and an automatic threshold directly solves the delay B admitted kills people. This exchange collapsed B's alternative and anchored A's weighing framework.

## Debate B

- Transcript: [read the full debate](../../../transcripts/prop_0606__ernie-5.1__claude-opus-4-8-adaptive__s1__tpl_placement_active_20260320f.md)
- Roles: PRO = **Baidu Ernie 5.1**, CON = **Claude Opus 4.8 (high)**
- Judged result: Unanimous `3-0` for **Claude Opus 4.8 (high)**.
- Entertainment scores: `7`, `8`, `8`
- Mean signed raw margin (PRO+): `-2.10`

| Judge | Presented sides | Winner | Signed Margin (PRO+) | Normalized | Entertainment |
| --- | --- | --- | ---: | ---: | ---: |
| Grok 4.3 | A = Claude Opus 4.8 (high) (CON); B = Baidu Ernie 5.1 (PRO) | Claude Opus 4.8 (high) | -2.2 | -2.64 | 7.0 |
| Kimi K2.6 | A = Claude Opus 4.8 (high) (CON); B = Baidu Ernie 5.1 (PRO) | Claude Opus 4.8 (high) | -1.6 | -1.60 | 8.0 |
| Qwen 3.6 Max Preview | A = Baidu Ernie 5.1 (PRO); B = Claude Opus 4.8 (high) (CON) | Claude Opus 4.8 (high) | -2.5 | -2.50 | 8.0 |

### Judge Notes

- **Grok 4.3** (A = Claude Opus 4.8 (high) (CON); B = Baidu Ernie 5.1 (PRO)): Side A wins by exposing an unresolvable calibration dilemma (the trigger is either redundant or destructive) and showing all cited gains came from existing discretionary TRIPS tools, not the automatic formula. Side B concedes the dilemma in rebuttals and never names a safe yet meaningful line. A's rebuttals directly damage B's live routes on certainty, capacity, and novelty.
  Most decisive rebuttal noted: A2.2/A2.3 trap (tiered pricing both saves and dooms the trigger) plus A4.7 crystallization of the dormant-vs-fires-everywhere admission.
- **Kimi K2.6** (A = Claude Opus 4.8 (high) (CON); B = Baidu Ernie 5.1 (PRO)): Side A (CON) won by exposing a fatal calibration dilemma that Side B (PRO) never resolved: any automatic affordability threshold is either set high enough to be redundant (because voluntary tiered pricing already keeps prices below it) or low enough to be destructive (firing across nearly every patented drug in poor markets and signaling presumptive expropriation). PRO conceded both states in their rebuttals but called them a "safety net," without explaining how the automatic formula adds value when dormant or how it avoids deterring launches when active. CON also turned PRO's own evidence against them, showing that every cited success—Brazil, Thailand, Hep C, India—came from discretionary leverage that already exists under TRIPS, not from an automatic trigger. PRO's claim that automaticity provides beneficial "certainty" was effectively turned into a liability, as firms facing automatic patent voidance with no room to demonstrate cost justification have incentives to delay or skip registration in poor markets. Finally, PRO's Rebuttal 2 was clipped for exceeding the word limit, leaving key burdens partially unaddressed and creating a real execution cost.
  Most decisive rebuttal noted: Side A's Rebuttal 1 (A2), where CON identified that PRO's attempt to make the trigger look safe relied on tiered pricing—the voluntary tool PRO dismissed—thereby proving the trigger is either useless or dangerous. This dilemma framing became the central unresolved clash that PRO never escaped.
- **Qwen 3.6 Max Preview** (A = Baidu Ernie 5.1 (PRO); B = Claude Opus 4.8 (high) (CON)): Side B isolated the motion's unique mechanism (automaticity versus existing discretionary TRIPS leverage) and built a decisive redundant-versus-reckless calibration dilemma. Side B neutralized Side A's historical examples by showing they relied on case-by-case judgment, not an automatic formula, and sharply exploited Side A's concession that the trigger would sit dormant when tiered pricing works. Side A's appeals to certainty and speed failed to answer the launch-delay risk or escape the structural trap. Side B's tighter framing, superior weighing, and disciplined rebuttals secure a clear win.
  Most decisive rebuttal noted: Side B's second rebuttal and closing dismantling Side A's calibration dilemma. By highlighting Side A's admission that the rule sits dormant when voluntary pricing works, Side B locked in the redundant-or-reckless trap and turned Side A's certainty argument into a liability that guarantees market exit.

## Technical metadata

- Evaluation scope: `judge_judge_blend_glm53_coverage_20260904a__debate_all_templates`
- Topic ID: `prop_0606`
- Side-swap group ID: `prop_0606__claude-opus-4-8-adaptive__ernie-5.1__tpl_placement_active_20260320f`
- Raw paired winner: **Claude Opus 4.8 (high)**
- Mean normalized margin for Claude Opus 4.8 (high): `+2.19`
- Complete side swap: `yes`
- Included in ratings: `yes`
